

ONLINE SUPPLEMENTARY DATA

SUPPLEMENTARY TABLE 1. Number (%) of patients with PIC or GO deformity at baseline and Week 24 by reader (full analysis set for structural damage endpoints)

	IV Placebo	IV Golimumab 2 mg/kg
Patients randomized, n	239	241
Patients with both baseline and Week 24 evaluations	215	231
Reader 1		
PIC or GO at baseline	8 (3.7)	5 (2.2)
PIC or GO at Week 24	9 (4.2)	5 (2.2)
Reader 2		
PIC or GO at baseline	23 (10.7)	20 (8.7)
PIC or GO at Week 24	24 (11.2)	21 (9.1)

GO – gross osteolysis, PIC – pencil-in-cup

SUPPLEMENTARY FIGURE 1. Cumulative probability plots of changes in total PsA-modified SHS at week 24 (full analysis set for structural damage endpoints) for patients with (A) and without (B) NSAID use at baseline and for patients with (C) and without (D) oral low-dose corticosteroid use at baseline. *NSAID – nonsteroidal anti-inflammatory drug, PsA – psoriatic arthritis, SDC – smallest detectable change, SHS - Sharp/van der Heijde Score*

